SOM 0044
Alternative Names: SOM-0044Latest Information Update: 28 Nov 2024
At a glance
- Originator SOM Biotech
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Parkinson's-disease in Spain
- 27 Oct 2020 SOM 0044 is available for licensing as of 27 Oct 2020. https://sombiotech.com/partnership-with-som-biotech/ (SOM Biotech website, October 2020)
- 27 Oct 2020 Preclinical trials in Parkinson's disease in Spain (unspecified route) before October 2020 (SOM Biotech website, October 2020)